Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fenretinide lipid matrix - BioMolecular Products/Lym-Drug Products

Drug Profile

Fenretinide lipid matrix - BioMolecular Products/Lym-Drug Products

Alternative Names: 4-HPR/LXS; Fenretinide LYM-X-SORB; HPR/LXS; LXS/4-HPR

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biomolecular Products; Lym-Drug Products LLC
  • Developer Academic Medical Center; Childrens Hospital Los Angeles; National Cancer Institute (USA)
  • Class Antineoplastics; Antivirals; Chemopreventatives; Retinoids; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Insulin resistance
  • No development reported Lymphoma; Neuroblastoma; Solid tumours

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for phase-I development in Lymphoma in USA (PO, Controlled release)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in Neuroblastoma(Combination therapy, Recurrent) in USA (PO, Controlled release)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in Neuroblastoma(Recurrent) in USA (PO, Controlled release)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top